Organon (OGN)
13.78
+0.01 (0.07%)
Upcoming Events
Latest Headlines
Orogen Royalties acquires two Utah gold projects with Triple Flag
September 2, 2026 8:01 AM - StreetInsider
Orogen Royalties Acquires Two Gold Projects in Southwest Utah
September 2, 2026 8:01 AM - StreetInsider
National Can-RISE Study to Help Close Critical Gaps in Menopause Research
August 27, 2026 9:00 AM - Globe NewsWire
Form 4 Organon & Co. For: Aug 11 Filed by: Arjona Ferreira Juan Camilo
August 12, 2026 1:02 PM - SEC Filing
Organon opens REMS enrollment for copper IUD ahead of late 2026 launch
August 11, 2026 7:31 AM - StreetInsider
Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability
August 11, 2026 7:30 AM - BizWire
Form 4 Organon & Co. For: Aug 05 Filed by: Drinane Juliana Papa
August 5, 2026 4:05 PM - SEC Filing
Organon Announces Quarterly Dividend
July 31, 2026 8:30 AM - BizWire
Organon (OGN) Declares $0.02 Quarterly Dividend; 0.6% Yield
July 31, 2026 8:30 AM - StreetInsider
Organon presents tapinarof cream data across age groups at SPD meeting
July 24, 2026 8:00 AM - StreetInsider
New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults¹
July 24, 2026 8:00 AM - BizWire
Altius Provides 2nd Quarter 2026 Project Generation Update
July 17, 2026 7:45 AM - BizWire
Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
July 16, 2026 7:30 AM - BizWire
Organon to present tapinarof cream data at pediatric dermatology meeting
July 7, 2026 8:01 AM - StreetInsider
Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting
July 7, 2026 8:00 AM - BizWire
Organon launches two denosumab biosimilars in Canada
June 23, 2026 5:38 AM - StreetInsider
Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVA
June 23, 2026 5:30 AM - BizWire
Organon closes license deal for copper IUD Miudella with Sebela
June 22, 2026 7:30 AM - StreetInsider
Organon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device
June 22, 2026 7:30 AM - BizWire
Organon and Samsung Bioepis add ustekinumab biosimilar to Canada deal
June 18, 2026 6:01 AM - StreetInsider
Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in Canada
June 18, 2026 6:00 AM - BizWire
Form 4 Organon & Co. For: Jun 12 Filed by: Sharp Shalini
June 15, 2026 4:42 PM - SEC Filing
Form 4 Organon & Co. For: Jun 12 Filed by: Sequeira Ramona
June 15, 2026 4:41 PM - SEC Filing
Form 4 Organon & Co. For: Jun 12 Filed by: Patton Cynthia M
June 15, 2026 4:40 PM - SEC Filing
Form 4 Organon & Co. For: Jun 12 Filed by: Ozuah Philip
June 15, 2026 4:39 PM - SEC Filing
Form 4 Organon & Co. For: Jun 12 Filed by: Leone Deborah R
June 15, 2026 4:38 PM - SEC Filing
Form 4 Organon & Co. For: Jun 12 Filed by: LAZARUS ROCHELLE B
June 15, 2026 4:37 PM - SEC Filing
Form 4 Organon & Co. For: Jun 12 Filed by: Gayle Helene D
June 15, 2026 4:35 PM - SEC Filing
Form 4 Organon & Co. For: Jun 12 Filed by: Ezekowitz Alan
June 15, 2026 4:34 PM - SEC Filing
Form 4 Organon & Co. For: Jun 12 Filed by: ESSNER ROBERT
June 15, 2026 4:32 PM - SEC Filing
Organon gets FDA approval for expanded TOFIDENCE uses
June 10, 2026 7:30 AM - StreetInsider
Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19
June 10, 2026 7:30 AM - BizWire
Full Article List
